EDITOR'S CORNER Human Vaccines & Immunotherapeutics 11:11, 2513; November 2015; © 2015 Taylor & Francis Group, LLC

Letter from the Editor Dear reader, We start this issue of Human Vaccines & Immunotherapeutics with a Portrait of Prof. Edward Rybicki of University of Cape Town, South Africa (p 2517), in which you can find out about plant virology and vaccine ‘biofarming.’ Next we introduce a Special Focus on Vaccines and Vaccination for Special Populations, which reviews the requirements, recommendations, optimal schedules, and potential benefits and risks in immunization of special populations, such as cancer patients, preterm infants, prisoners and others. A particularly exposed group is healthcare workers—the specific risks and potential interventions to increase coverage are discussed by Haviari and colleagues (p 2522). Three reviews look at immunization in pregnant women and infants: the impact of maternal influenza vaccination on preterm births (Nunes, p 2538), systematic literature review of recommendations, schedule, benefits and risks of vaccination in pregnancy (Faucette, p 2549), and immunization of preterm infants, which is often delayed even though this group is at higher risk (Gagneur, p 2556). The Special Focus also presents reviews of vaccination of children with secondary immunodeficiency, such as HIV and cancer patients, transplant recipients and children with autoimmune disease (Esposito, p 2564), adolescents with chronic medical conditions, who should often receive vaccines in addition to the routine ones (Hofstetter, p 2571), and hepatitis A and B vaccination in HIV-infected adults (Mena, p 2582). A review investigates hepatitis B, influenza and pneumococcal immunizations in chronic kidney disease (Grzegorzewska, p 2599), and specific aspects are reviewed in vaccination of adult cancer patients (Ariza-Heredia, p 2606), prisoners (Sequera, p 2615) and refugees and internally-displaced people (Lam, p 2627). The Special Focus section concludes with a research study of the population of nomadic children in Somalia with emphasis on polio vaccination (Kamadjeu, p 2637). We are happy to present a Meeting Supplement from the International Workshop on Human Vaccines and Immunotherapy held in Shanghai, August 18–21, 2015. This section features four articles by leading scientists from China, as detailed in the Editorial introduction (Li, p 2640). The Immunotherapy section contains a preclinical study of a cancer antigen NY-ESO-1 delivered by recombinant Lactobacillus plantarum (Mobergslien, p 2664), a report on novel immunotherapy of Alzheimer’s disease and how it alleviates symptoms in a mouse model (Zhang, p 2674), and a commentary on ultrasound-induced blood-brain barrier opening and its use in immune modulation (Chen, p 2682). Two articles on Novel Vaccines are introduced: a review of the feasibility of a multivalent hand, foot and mouth disease vaccine (Klein, p 2688) and a study of a malaria vaccine candidate based on a DNA prime encoding CSP and an adenovirus boost carrying AMA1 (Sedegah, p 2705). In addition, we present studies of immune response to Hepatitis B revaccination in adult non-responders (Zhang, p 2716), the compatibility of Enterovirus-71 vaccine candidate with Licensed Vaccines, namely, Coxsackievirus A16 and Poliovirus vaccines (Mao, p 2723), the development of Vipera lebetina snake antivenom for Passive Immunization (Zolfagharian, p 2734), and a case report of Kawasaki disease following routine vaccinations (Yin, p 2740). Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome! Sincerely, Ronald Ellis, PhD Editor-in-Chief Adam Weiss Acquisitions Editor http://dx.doi.org/10.1080/21645515.2015.1106800


Human Vaccines & Immunotherapeutics


Letter from the Editor.

Letter from the Editor. - PDF Download Free
NAN Sizes 2 Downloads 9 Views